Drugs / CART84
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07471789 | Feb 2026 → May 2029 expected | T-cell acute lymphoblastic leukemia, acute myeloid leukemia | Gyala Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART84 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07471789 ↗ |
| Known as | GYA01 | “GYA01 (CART84): autologous cell-based product containing CD3+ T cells transduced with a lentiviral vector expressing an anti-CD84 chimeric antigen receptor (CAR).” NCT07471789 ↗ |
| Modality | Cell therapy | “GYA01 (CART84) is a type of CAR T-cell therapy.” NCT07471789 ↗ |
| Route | Intravenous | “given back to the participant through an infusion into a vein.” NCT07471789 ↗ |
| Target | CD84 | “expressing an anti-CD84 chimeric antigen receptor (CAR).” NCT07471789 ↗ |